Skip to main content
. 2014 Jan 2;124(2):553–563. doi: 10.1172/JCI69804

Figure 6. Endogenous EPO expression correlates negatively with relapse-free survival and is produced by breast cancer cell lines and tumor endothelial cells.

Figure 6

(A) Breast tumors (337 patients [GSE18229] and 855 patients [GSE26338] were rank ordered based on their EPO expression and divided into those with high and low EPO expression (high: top 2 tertiles, low: bottom tertile). P = 0.0088 for UNC337, P = 0.0012 for GSE26338, log rank test. (B) EPO mRNA levels from HMECs and the indicated breast cancer cell lines cultured in 21% and 1% O2 using TaqMan quantitative RT-PCR. (C) EPO protein as measured by ELISA on conditioned medium from the indicated cell lines after culture under 21% O2 or 1% O2 for 16 hours. (D) Microarray gene expression for EPO was abstracted from a publically available data set (GSE7413) in which breast cancer–associated endothelial cells or endothelial cells from adjacent normal were laser capture microdissected. Relative gene expression Cy5 (tumor)/Cy3(reference) is shown. (E) EPO mRNA levels from HUVECs cultured in 21% and 1% O2 were measured by TaqMan quantitative PCR. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.